Omniab Inc (OABI) Stock Price, Quote & News

Company Profile

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 250 7800

Website: www.omniab.com

Address:

5980 Horton Street, Suite 600, EmeryVille, United States

a36er Oct. 23 at 3:17 PM

$OABI 25K bid at 1.62 on the NAZ.....

0 · Reply

bearsoil Oct. 21 at 6:05 PM

$OABI Hopefully the upcoming earnings conference call will shed some light on revenue guidance past the next 2 quarters The trading volume has been extremely low. The upcoming road shows need to draw some interest. While there hasn’t been a lot of buying there certainly haven’t been any heavy sellers Lots of potential here.Ligand has certainly established a great record of success with their spinoffs

0 · Reply

hichemben Oct. 16 at 8:49 AM

$OABI 🚀

1 · Reply

PlannedTrading101 Oct. 9 at 3:38 PM

$OABI Ready to blast off!

0 · Reply

AIAdept Oct. 5 at 3:12 PM

$OABI SPAC structure. Pre-merger speculation. Trading near trust value. Redemption risk present.

1 · Reply

a36er Sep. 29 at 7:54 PM

$OABI At 3:44pm a block of 1.4M traded.

1 · Reply

bearsoil Sep. 25 at 11:35 PM

$OABI OABI Business model is different than most biotechs. That’s why it’s having a hard time gaining traction. It depends on its customers success more than developing its own drugs through trials. Wall Street has a hard time valuing a biotech license company. Especially an early stage company like AOBI. Right now investors are just looking at the cash burn rate. They have big name customers but with confidential agreements set up we dont see many press releases about specific deals. You have to wait for each quarter CC to get any color of progress. All that being said makes it challenging to get any significant volume for a penny stock However their science is unique and eventually customer growth will show up. Reminds me of another LGND spinoff VKTX when you couldn’t give it away at1.25 This low price on OABI won’t last forever

1 · Reply

bearsoil Sep. 19 at 8:22 PM

$OABI Large trades in last few minutes Once insttutions realize some of the big name companies that OABI has as customers stock should treade up from this low price

1 · Reply

PlannedTrading101 Sep. 17 at 7:50 PM

$OABI Still here accumulating. I am positive this will have a nice run from these levels.

0 · Reply

bearsoil Sep. 15 at 9:38 PM

$OABI Large trading volume during the last hour. Interesting science. Great potential. But boy do they spend a lot on R and D. Different than clinical trials as far as time frames but expensive testing. Once some daylight on significant revenues are seen this stock should move up.

0 · Reply

OmniAb to Participate in Three Investor Conferences in November

Oct 14, 2025, 8:00 AM EDT - 13 days ago

OmniAb to Report Third Quarter 2025 Financial Results on November 4

Sep 2, 2025, 8:00 AM EDT - 7 weeks ago

OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:12 AM EDT - 2 months ago

Top 3 Health Care Stocks You'll Regret Missing This Quarter

NNOX ZTEK

Aug 25, 2025, 7:00 AM EDT - 2 months ago

OmniAb Announces $30 Million Private Placement

Aug 7, 2025, 2:24 AM EDT - 2 months ago

OmniAb, Inc. (OABI) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 2 months ago

OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights

Jul 16, 2025, 8:00 AM EDT - 3 months ago

OmniAb to Report Second Quarter 2025 Financial Results on August 6

May 13, 2025, 4:05 PM EDT - 5 months ago

OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit

May 10, 2025, 3:52 AM EDT - 6 months ago

OmniAb, Inc. (OABI) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:06 PM EDT - 6 months ago

OmniAb Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:05 PM EDT - 6 months ago

OmniAb Introduces the xPloration® Partner Access Program

May 5, 2025, 1:00 AM EDT - 6 months ago

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

May 1, 2025, 8:00 AM EDT - 6 months ago

OmniAb to Participate in Five Upcoming Investor Conferences

Apr 21, 2025, 8:00 AM EDT - 6 months ago

OmniAb Announces Two New Appointments to its Board of Directors

Mar 18, 2025, 7:37 PM EDT - 7 months ago

OmniAb, Inc. (OABI) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 4:05 PM EDT - 7 months ago

OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 24, 2025, 8:00 AM EST - 8 months ago

OmniAb to Report Fourth Quarter 2024 Financial Results on March 18

Feb 3, 2025, 4:57 PM EST - 9 months ago

OmniAb to Participate in Two Investor Conferences in March

Jan 31, 2025, 11:09 AM EST - 9 months ago

Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm

Dec 16, 2024, 4:15 PM EST - 11 months ago

OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference

Nov 12, 2024, 9:53 PM EST - 1 year ago

OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 1 year ago

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

Oct 30, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Participate in Two Investor Conferences in November

Oct 22, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Report Third Quarter 2024 Financial Results on November 12

Aug 26, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Participate in Two Investor Conferences in September

Aug 10, 2024, 11:28 AM EDT - 1 year ago

OmniAb, Inc. (OABI) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 6, 2024, 8:25 AM EDT - 1 year ago

Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging

FIP FTAI IMVT PRPL REAL RICK

Jul 25, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Report Second Quarter 2024 Financial Results on August 8

Jun 3, 2024, 4:05 PM EDT - 1 year ago

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology

May 20, 2024, 8:05 AM EDT - 1 year ago

OmniAb to Participate in the Jefferies Global Healthcare Conference

May 15, 2024, 4:05 PM EDT - 1 year ago

OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit

May 10, 2024, 4:33 PM EDT - 1 year ago

OmniAb, Inc. (OABI) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 1 year ago

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

May 1, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Participate in Five Investor Conferences in May

Apr 22, 2024, 8:00 AM EDT - 1 year ago

OmniAb to Report First Quarter 2024 Financial Results on May 9

Apr 15, 2024, 8:31 AM EDT - 1 year ago

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

THAR

Mar 20, 2024, 7:38 PM EDT - 1 year ago

OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 4:05 PM EDT - 1 year ago

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 26, 2024, 8:00 AM EST - 1 year ago

OmniAb to Report Fourth Quarter 2023 Financial Results on March 20

Dec 14, 2023, 4:30 PM EST - 2 years ago

OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference

Nov 14, 2023, 12:44 PM EST - 2 years ago

OmniAb, Inc. (OABI) Research and Technology Virtual Event and Q3 2023 Earnings Call Transcript

Nov 9, 2023, 5:55 PM EST - 2 years ago

OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today's Research & Technology Virtual Event

Nov 9, 2023, 8:00 AM EST - 2 years ago

OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 1, 2023, 9:00 AM EDT - 2 years ago

OmniAb Appoints Steve Love to its Board of Directors

Oct 31, 2023, 4:28 PM EDT - 2 years ago

OmniAb Announces Agenda for its Research & Technology Virtual Event

Oct 12, 2023, 8:00 AM EDT - 2 years ago

OmniAb to Hold Research & Technology Virtual Event on November 9

Sep 25, 2023, 9:22 PM EDT - 2 years ago

OmniAb: Hold For Growth

Aug 12, 2023, 2:39 PM EDT - 2 years ago

OmniAb, Inc. (OABI) Q2 2023 Earnings Call Transcript

a36er Oct. 23 at 3:17 PM

$OABI 25K bid at 1.62 on the NAZ.....

0 · Reply

bearsoil Oct. 21 at 6:05 PM

0 · Reply

hichemben Oct. 16 at 8:49 AM

$OABI 🚀

1 · Reply

PlannedTrading101 Oct. 9 at 3:38 PM

$OABI Ready to blast off!

0 · Reply

AIAdept Oct. 5 at 3:12 PM

$OABI SPAC structure. Pre-merger speculation. Trading near trust value. Redemption risk present.

1 · Reply

a36er Sep. 29 at 7:54 PM

$OABI At 3:44pm a block of 1.4M traded.

1 · Reply

bearsoil Sep. 25 at 11:35 PM

1 · Reply

bearsoil Sep. 19 at 8:22 PM

$OABI Large trades in last few minutes Once insttutions realize some of the big name companies that OABI has as customers stock should treade up from this low price

1 · Reply

PlannedTrading101 Sep. 17 at 7:50 PM

$OABI Still here accumulating. I am positive this will have a nice run from these levels.

0 · Reply

bearsoil Sep. 15 at 9:38 PM

0 · Reply

DARKP00L Sep. 12 at 8:15 PM

$OABI 16:05 on Sep. 12 2025 OmniAb Files For Offering Of 21.3M Shares By Selling Stockholders #tradeideas

0 · Reply

NVDAMillionaire Sep. 10 at 7:28 AM

$OABI Great piece that accurately captures OABI's current position. So if you want to refresh your understanding of OABI or learn about OABI for the first time, this is essential reading. https://beyondspx.com/quote/OABI/analysis/omniab-unlocking-antibody-discovery-through-biological-intelligence-and-strategic-innovation-nasdaq-oabi

1 · Reply

DARKP00L Sep. 4 at 2:10 PM

$OABI this stock is attracting a lot of interest. Be prepared for possible changes!

0 · Reply

tranq19 Aug. 26 at 8:13 PM

$OABI at least Foehr picked up another 500k shares in the offering at 1.85

1 · Reply

The300 Aug. 26 at 11:48 AM

$OABI business drying up as the main platform (omniab rats) has become a commodity. management diluting shareholders and flaying around for new sources of revenue while they wait (years!) for royalties to kick in. The obvious move would be to shut down operations, send cash back to shareholder, and hibernate until royalties mature…. but they won’t…

0 · Reply

OpenOutcrier Aug. 25 at 12:50 PM

$OABI (-9.2% pre) OmniAb raises $30 million in private placement at $1.40 per share https://ooc.bz/l/75062

2 · Reply

DonCorleone77 Aug. 25 at 11:16 AM

$OABI OmniAb to sell 21.254M shares at $1.40 in private placement

0 · Reply

PlannedTrading101 Aug. 22 at 5:48 PM

$OABI Still accumulating here. Chart looks solid. Just needs some volume or positive news and this goes fast IMO.

0 · Reply

bearsoil Aug. 20 at 7:45 PM

$OABI Selloff on low volume Price point at 1.85 looking attractive

0 · Reply

PlannedTrading101 Aug. 13 at 2:24 PM

$OABI Ready to breakout!! Cmon lets go!

0 · Reply

PlannedTrading101 Aug. 8 at 3:19 PM

$OABI Still accumulating under 2.00. This will be a nice winner IMO. Price targets from $4-$11

0 · Reply

JarvisFlow Aug. 7 at 3:12 PM

RBC Capital has adjusted their stance on OmniAb ( $OABI ), setting the rating to Outperform with a target price of 4 → 3.

0 · Reply

Market Cap	234.65M
Revenue (ttm)	26.39M
Net Income (ttm)	-62.03M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-235.05%
Debt to Equity Ratio	0.00

Volume	279,716
Avg Vol	492,266
Day's Range	N/A - N/A
Shares Out	143.96M
Stochastic %K	20%
Beta	0.15
Analysts	Strong Sell
Price Target	$7.71